Majority of the reports suggested a positive response to the treatment and a manageable toxicity profile with neutropenia being the most common adverse event, but, it is also known that barasertib at higher concentrations inhibits FLT3 and KIT kinases required for hematopoiesis and hence may result in dose-limiting neutropenia [78,79]. This evidence concerns the gene FLT3 and neutropenia.